Trillium Health commits to uninterrupted drug access in light of Daraprim news

September 24, 2015

Jason Roberts, Community Engagement & Innovation

Rochester, NY - Trillium Health is committed to providing comprehensive and barrier-free healthcare to our Patients. We, like many of our colleagues in the healthcare industry, are concerned about Turing Pharmaceuticals price increase of the drug Daraprim - a medication used to treat toxoplasmosis, an AIDS-related opportunistic infection. 

As a healthcare center with a legacy of providing care to those impacted by HIV/AIDS, we want to assure our Patients and the greater community that Patient-access to this drug will remain uninterrupted and that our team of Providers and Clinical Pharmacists will continue to explore innovative treatments best-suited for our Patients. 

We will also continue to closely monitor industry access to medications for pharmacies and health centers like ours. Both Trillium Health and the Pharmacy at Trillium Health are committed to this concern and join our industry professionals in ensuring this issue does not become a growing trend.

for additional  information, consider:

 


« Go Back